Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) Director Frank Karbe bought 12,500 shares of the stock in a transaction dated Friday, December 13th. The shares were bought at an average cost of $7.93 per share, with a total value of $99,125.00. Following the completion of the acquisition, the director now directly owns 57,000 shares of the company's stock, valued at approximately $452,010. The trade was a 28.09 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Phathom Pharmaceuticals Trading Up 3.2 %
Shares of NASDAQ PHAT opened at $8.14 on Tuesday. Phathom Pharmaceuticals, Inc. has a 12-month low of $6.07 and a 12-month high of $19.71. The company has a market cap of $556.61 million, a PE ratio of -1.43 and a beta of 0.56. The stock has a 50 day simple moving average of $12.74 and a 200-day simple moving average of $13.17.
Analyst Upgrades and Downgrades
A number of research analysts recently commented on PHAT shares. Needham & Company LLC restated a "buy" rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a research note on Wednesday, December 11th. HC Wainwright reissued a "buy" rating and set a $28.00 price target on shares of Phathom Pharmaceuticals in a report on Thursday, December 12th.
I was wrong. Dead wrong.
From Porter & Company | Ad
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was.
Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Here’s the full story for you.
Check Out Our Latest Research Report on PHAT
Institutional Trading of Phathom Pharmaceuticals
Hedge funds have recently added to or reduced their stakes in the business. Huntington National Bank increased its holdings in shares of Phathom Pharmaceuticals by 62.2% during the third quarter. Huntington National Bank now owns 1,471 shares of the company's stock valued at $27,000 after purchasing an additional 564 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in Phathom Pharmaceuticals by 41.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,470 shares of the company's stock valued at $43,000 after buying an additional 722 shares in the last quarter. US Bancorp DE increased its stake in Phathom Pharmaceuticals by 28.6% during the 3rd quarter. US Bancorp DE now owns 5,248 shares of the company's stock valued at $95,000 after buying an additional 1,166 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Phathom Pharmaceuticals by 42.2% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,071 shares of the company's stock worth $104,000 after buying an additional 2,987 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Phathom Pharmaceuticals by 10.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,941 shares of the company's stock worth $144,000 after acquiring an additional 1,339 shares during the period. Institutional investors own 99.01% of the company's stock.
About Phathom Pharmaceuticals
(
Get Free Report)
Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
